Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

25.62 -0.39 (-1.50%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts ↗

August 17, 2026

Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient discontinuations...

Via MarketBeat

Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript ↗

August 10, 2026

Phase III enrollment complete for zorevunersen with zero discontinuation rates.

Via The Motley Fool

Topics Earnings

Stoke Therapeutics Q2 Earnings Call Highlights ↗

August 03, 2026

Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion...

Via MarketBeat

Topics Earnings

Stoke Therapeutics (NASDAQ:STOK) Beats Q1 2026 Estimates as Phase 3 Trial Nears Completion ↗

May 07, 2026

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Where Stoke Therapeutics Stands With Analysts ↗

August 13, 2025

Via Benzinga

A Look Ahead: Stoke Therapeutics's Earnings Forecast ↗

August 11, 2025

Via Benzinga

Stoke Therapeutics Q1 Earnings Call Highlights ↗

May 09, 2026

Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year...

Via MarketBeat

Topics Earnings

Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares ↗

March 27, 2026

This biotech innovator in genetic disease therapies reported a notable insider sale amid a year of dramatic share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss

March 26, 2026

The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which...

Via MarketMinute

Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally ↗

March 24, 2026

This RNA therapeutics innovator for rare diseases reported a notable insider sale amid a year of dramatic share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

Via The Motley Fool

Topics Regulatory Compliance

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

Top movers in Monday's pre-market session ↗

January 12, 2026

Via Chartmill

Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? ↗

December 10, 2025

This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗

December 09, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

6 Analysts Have This To Say About Stoke Therapeutics ↗

November 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

Examining the Future: Stoke Therapeutics's Earnings Outlook ↗

November 03, 2025

Via Benzinga

What 4 Analyst Ratings Have To Say About Stoke Therapeutics ↗

October 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 22, 2025

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday ↗

July 22, 2025

Via Benzinga

This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

July 18, 2025

Via Benzinga

STOKE THERAPEUTICS INC (NASDAQ:STOK) – A Biotech Stock with Strong Growth Signals ↗

May 29, 2025

STOKE THERAPEUTICS (NASDAQ:STOK) shows strong growth metrics, high profitability improvements, and attractive valuation, making it a candidate for growth investors following Louis Navellier's...

Via Chartmill

Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar ↗

May 01, 2025

The company beat first-quarter expectations, partly thanks to strong sales of its rare disease drugs.

Via Investor's Business Daily

Topics Earnings

Forecasting The Future: 7 Analyst Projections For Stoke Therapeutics ↗

March 18, 2025

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.